FORM 3

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235- 0104					
Estimated average burden						
hours per	0.5					

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Behbahani Ali</u>	Requiring (Month/D	2. Date of Event Requiring Statement (Month/Day/Year) 06/23/2021  3. Issuer Name and Ticker or Trading Symbol Monte Rosa Therapeutics, Inc. [ GLUE ]								
(Last) (First) (Middle) 1954 GREENSPRING DRIVE			Relationship of Reporting Issuer (Check all applicable)	· ·	` ,	5. If Amendment, Date of Original Filed (Month/Day/Year)				
SUITE 600	_		X Director Officer (give title below)	Othe	X 10% Owner Other (specify below)		6. Individual or Joint/Group Filing (Check Applicable Line)  Form filed by One Reporting			
(Street) TIMONIUM MD 21093 (City) (State) (Zip)			title below)	belo	w)	X	Person	y More than One		
Table I - Non-Derivative Securities Beneficially Owned										
			2. Amount of Securities Beneficially Owned (Inst 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)			4. Nature of Indirect Beneficial Ownership (Instr. 5)			
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)										
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		Underlying Derivative Security (Instr. 4)		4. Conve	ercise	5. Ownership Form:	6. Nature of Indirect Beneficial		
	Date Exercisable	Expiration Date	Title	Amount of Number of Shares		tive	Direct (D) or Indirect (I) (Instr. 5)	Ownership (Instr. 5)		
Series A-2 convertible preferred stock	(1)	(1)	Common Stock	2,715,96	8	1)	I	See Note 2 <sup>(2)</sup>		
Series B convertible preferred stock	(1)	(1)	Common Stock	3,257,32	18	1)	I	See Note 2 <sup>(2)</sup>		
Series C convertible preferred stock	(1)	(1)	Common Stock	669,00	2 (1	1)	I	See Note 2 <sup>(2)</sup>		

## **Explanation of Responses:**

- 1. Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") is convertible into shares of the Issuer's Common Stock on a 3.5305-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 3. The Preferred Stock has no expiration date.
- 2. The Reporting Person is a manager of NEA 17 GP, LLC ("NEA 17 GP"), which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

## Remarks:

<u>/s/ Sasha Keough,</u> attorney-in-fact

06/23/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.